Thus, targeting the hRNase 1–EphA4 axis may be a promising therapeutic strategy against breast cancer by decreasing tumor-initiating capability and may open a new direction that has been overlooked in our understanding of receptor biology in cancer progression. Here, EPHA4 is linked to breast carcinoma.